You must be new to the THLD story. As this is a rehash of plenty of previous postings we will give you a pass. Unfortunately it does not into the more significant issues that have been raised in the professional investment community.
2013 GU: Dendreon's Neuvenge, A First Look At The Clinical Trial Results [View article]
This is another one that fits right in along with DVAX---where the ship has sailed. I'm always amazed how people defend their losing positions and become more entrenched as they crumble in value.
Betting Splunk Goes Splat [View article]
Dynavax: A Takeover Target? [View article]
Dynavax: The Path Forward [View article]
Dendreon: Startling Results Sequencing Provenge After Medivation's Xtandi [View article]
Dynavax Initiates New Phase I Trial For Lymphomas [View article]
A Biotech Winner For 2013 [View article]
Good luck in your investment career.
2013 GU: Dendreon's Neuvenge, A First Look At The Clinical Trial Results [View article]
Betting Splunk Goes Splat [View article]
The Market Is Starting To Feel Toppy [View article]
Sarepta Recovers Lost Ground With Bullish Analyst Activity [View article]
Betting Splunk Goes Splat [View article]
Today's Market News To Trade On: 5 Stocks Moving On News [View article]
Betting Splunk Goes Splat [View article]
'Top Of The Class' Small Pharma Investments For 2013 [View article]
Upcoming FDA Approval Decision Dates For Q1 2013 [View article]